Enjaymo (sutimlimab)

Recommended Dosage:

To optimize Sutimlimab treatment outcomes, vaccination against encapsulated bacteria should be administered at least two weeks before commencing treatment. The dosage, personalized based on weight, involves a weekly application for the initial two weeks, followed by a biweekly schedule thereafter:

• Patients weighing 39 kg to less than 75 kg: 6,500 mg via intravenous infusion
• Patients weighing 75 kg or more: 7,500 mg via intravenous infusion.

• Serious Infections: Prioritize patient safety by ensuring vaccination against encapsulated bacteria and vigilantly monitoring for early signs and symptoms of infections.
• Infusion-Related Reactions: Maintain a watchful eye on patients during infusions, promptly addressing any reactions and implementing appropriate medical management as necessary.
• Risk of Autoimmune Disease: Consistently monitor patients for signs and symptoms, proactively managing any emerging autoimmune concerns.
• Recurrent Hemolysis After ENJAYMO 50 mg/mL Discontinuation: Exercise diligence in monitoring patients for signs and symptoms of hemolysis should treatment with ENJAYMO be interrupted.

Documentation & Availability in India:
If you are considering the import of Enjaymo (Sutimlimab) to India, please be aware that Enjaymo can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

• Required Documentation for Import:
• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.

Government-issued identification proof for the patient, as recognized by the Government of India.
Order Confirmation Process: 
The order for Enjaymo (Sutimlimab) will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
• An import permit, if applicable

If you are considering the import of Enjaymo (Sutimlimab) to India, please be aware that Enjaymo can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

The order for Enjaymo (Sutimlimab) will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
• An import permit, if applicable.
• Availability of Enjaymo (Sutimlimab) in India: 

Enjaymo (Sutimlimab) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Enjaymo can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Enjaymo 50 mg vial (prescription medicines) to locations both within India and worldwide while adhering to relevant legal requirements.

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.